Enhancing ER stress in myeloma
- PMID: 28758893
- PMCID: PMC5559166
- DOI: 10.18632/aging.101273
Enhancing ER stress in myeloma
Keywords: ER stress; myeloma; proteasome inhibitor; sphingolipids.
Similar articles
-
Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.Oncotarget. 2017 Jul 4;8(27):43602-43616. doi: 10.18632/oncotarget.17115. Oncotarget. 2017. PMID: 28467788 Free PMC article.
-
Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.Int J Hematol. 2016 Sep;104(3):273-80. doi: 10.1007/s12185-016-2016-0. Epub 2016 May 12. Int J Hematol. 2016. PMID: 27169614 Review.
-
Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.Asia Pac J Clin Oncol. 2021 Feb;17(1):29-35. doi: 10.1111/ajco.13459. Epub 2020 Sep 13. Asia Pac J Clin Oncol. 2021. PMID: 32920949 Review.
-
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Oncogene. 2017 Oct 5;36(40):5631-5638. doi: 10.1038/onc.2017.172. Epub 2017 Jun 5. Oncogene. 2017. PMID: 28581522 Free PMC article.
-
[Research Progress on Molecular Mechanisms of Resistance to Bortezomib in Multiple Myeloma- Review].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Oct;25(5):1576-1579. doi: 10.7534/j.issn.1009-2137.2017.05.052. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017. PMID: 29070146 Review. Chinese.
Cited by
-
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells.Cancers (Basel). 2019 Mar 28;11(4):439. doi: 10.3390/cancers11040439. Cancers (Basel). 2019. PMID: 30925767 Free PMC article.
-
Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1.Viruses. 2018 Dec 24;11(1):8. doi: 10.3390/v11010008. Viruses. 2018. PMID: 30586869 Free PMC article.
-
GFI1-Dependent Repression of SGPP1 Increases Multiple Myeloma Cell Survival.Cancers (Basel). 2022 Feb 2;14(3):772. doi: 10.3390/cancers14030772. Cancers (Basel). 2022. PMID: 35159039 Free PMC article.
References
-
- Vincenz L, et al. Mol Cancer Ther. 2013;12:831–43. https://doi.org/10.1158/1535-7163.MCT-12-0782 - DOI - PubMed
-
- Obeng EA, et al. Blood. 2006;107:4907–16. https://doi.org/10.1182/blood-2005-08-3531 - DOI - PMC - PubMed
-
- Ocio EM, et al. Leukemia. 2014;28:525–42. https://doi.org/10.1038/leu.2013.350 - DOI - PMC - PubMed
-
- Volmer R, et al. Proc Natl Acad Sci USA. 2013;110:4628–33. https://doi.org/10.1073/pnas.1217611110 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical